Enanta Pharmaceuticals Inc (ENTA) — 10-Q Filings
All 10-Q filings from Enanta Pharmaceuticals Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Enanta Narrows Q3 Loss Amidst Reduced R&D Spending
— Aug 13, 2025 Risk: medium
Enanta Pharmaceuticals, Inc. reported a net loss of $18.255 million for the three months ended June 30, 2025, an improvement from the $22.658 million net loss i -
Enanta Pharma Q2 2025 Update: Royalty Deal Highlighted
— May 14, 2025 Risk: medium
Enanta Pharmaceuticals Inc. reported its Q2 2025 results, ending March 31, 2025. The company's filing details financial activities including research and develo -
Enanta Pharma Q1 2025 Update: Financials and Equity Awards
— Feb 12, 2025 Risk: low
Enanta Pharmaceuticals Inc. filed its 10-Q for the period ending December 31, 2024. The filing details financial information for the first quarter of fiscal yea -
Enanta Pharmaceuticals Files Q3 2024 10-Q
— Aug 7, 2024 Risk: medium
Enanta Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The company's f -
Enanta Pharmaceuticals Files 10-Q for Period Ending March 31, 2024
— May 8, 2024 Risk: low
ENANTA PHARMACEUTICALS INC (ENTA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Enanta Pharmaceuticals filed its 10-Q report for the period endin -
Enanta Pharmaceuticals Files 10-Q for Period Ending December 31, 2023
— Feb 8, 2024 Risk: low
ENANTA PHARMACEUTICALS INC (ENTA) filed a Quarterly Report (10-Q) with the SEC on February 8, 2024. Enanta Pharmaceuticals filed its 10-Q report for the period
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX